<?xml version='1.0' encoding='utf-8'?>
<document id="28705331"><sentence text="A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin."><entity charOffset="75-87" id="DDI-PubMed.28705331.s1.e0" text="methotrexate" /><entity charOffset="118-125" id="DDI-PubMed.28705331.s1.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.28705331.s1.e0" e2="DDI-PubMed.28705331.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28705331.s1.e0" e2="DDI-PubMed.28705331.s1.e1" /></sentence><sentence text="Methotrexate (MTX) is an antifolate drug, which is frequently used in the treatment of cancer"><entity charOffset="0-12" id="DDI-PubMed.28705331.s2.e0" text="Methotrexate" /><entity charOffset="14-17" id="DDI-PubMed.28705331.s2.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28705331.s2.e0" e2="DDI-PubMed.28705331.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28705331.s2.e0" e2="DDI-PubMed.28705331.s2.e1" /></sentence><sentence text=" Proton pump inhibitors (PPIs) could delay the elimination of plasma MTX in high-dose MTX therapy by inhibition of tubular secretion, which could lead to MTX toxicity"><entity charOffset="69-71" id="DDI-PubMed.28705331.s3.e0" text="MTX" /><entity charOffset="86-88" id="DDI-PubMed.28705331.s3.e1" text="MTX" /><entity charOffset="154-156" id="DDI-PubMed.28705331.s3.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28705331.s3.e0" e2="DDI-PubMed.28705331.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28705331.s3.e0" e2="DDI-PubMed.28705331.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28705331.s3.e0" e2="DDI-PubMed.28705331.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28705331.s3.e1" e2="DDI-PubMed.28705331.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28705331.s3.e1" e2="DDI-PubMed.28705331.s3.e2" /></sentence><sentence text=" However, the evidence of the clinical relevance of this drug-drug interaction is inconsistent" /><sentence text=" No previous studies into the effect of low dose aspirin on the elimination of MTX in high-dose therapy have been performed"><entity charOffset="49-56" id="DDI-PubMed.28705331.s5.e0" text="aspirin" /><entity charOffset="79-82" id="DDI-PubMed.28705331.s5.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28705331.s5.e0" e2="DDI-PubMed.28705331.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28705331.s5.e0" e2="DDI-PubMed.28705331.s5.e1" /></sentence><sentence text=" Therefore, we evaluated the interaction between MTX and PPIs or aspirin"><entity charOffset="65-72" id="DDI-PubMed.28705331.s6.e0" text="aspirin" /><entity charOffset="49-55" id="DDI-PubMed.28705331.s6.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28705331.s6.e1" e2="DDI-PubMed.28705331.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28705331.s6.e1" e2="DDI-PubMed.28705331.s6.e0" /></sentence><sentence text="" /><sentence text="We conducted a non-interventional retrospective cohort study in patients treated with high dose MTX (â‰¥500mg/m2 or &gt;1000mg), between 2009 and 2016 at the OLVG (&quot;Onze Lieve Vrouwe Gasthuis, Oost&quot;) in Amsterdam, the Netherlands"><entity charOffset="96-98" id="DDI-PubMed.28705331.s8.e0" text="MTX" /></sentence><sentence text=" Patients were included if MTX concentrations were determined at 24, 48 or 72hours after high dose MTX treatment"><entity charOffset="27-30" id="DDI-PubMed.28705331.s9.e0" text="MTX" /><entity charOffset="99-102" id="DDI-PubMed.28705331.s9.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28705331.s9.e0" e2="DDI-PubMed.28705331.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28705331.s9.e0" e2="DDI-PubMed.28705331.s9.e1" /></sentence><sentence text=" We categorised the cycles of high dose MTX therapy into delayed elimination or normal elimination"><entity charOffset="40-42" id="DDI-PubMed.28705331.s10.e0" text="MTX" /></sentence><sentence text=" Differences in patient characteristics and MTX dosing regimen were compared between all groups by X2-test, Fisher's exact probability test or Mann-Whitney U-test"><entity charOffset="44-46" id="DDI-PubMed.28705331.s11.e0" text="MTX" /></sentence><sentence text="" /><sentence text="In total, 89 high dose MTX cycles were included"><entity charOffset="23-25" id="DDI-PubMed.28705331.s13.e0" text="MTX" /></sentence><sentence text=" Delayed MTX elimination was observed in 27 (30"><entity charOffset="9-11" id="DDI-PubMed.28705331.s14.e0" text="MTX" /></sentence><sentence text="3%) cycles" /><sentence text=" Co-administration of a PPI was significantly more frequent in the delayed elimination group than in the normal elimination group (P&lt;0" /><sentence text="001)" /><sentence text=" There was no statistical effect observed by co-administration of aspirin"><entity charOffset="66-73" id="DDI-PubMed.28705331.s18.e0" text="aspirin" /></sentence><sentence text="" /><sentence text="The use of PPIs during high dose MTX treatment can lead to delayed MTX elimination"><entity charOffset="33-36" id="DDI-PubMed.28705331.s20.e0" text="MTX" /><entity charOffset="67-69" id="DDI-PubMed.28705331.s20.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28705331.s20.e0" e2="DDI-PubMed.28705331.s20.e0" /><pair ddi="false" e1="DDI-PubMed.28705331.s20.e0" e2="DDI-PubMed.28705331.s20.e1" /></sentence><sentence text=" Discontinuation of PPIs during high dose MTX treatment is recommended"><entity charOffset="42-45" id="DDI-PubMed.28705331.s21.e0" text="MTX" /></sentence><sentence text=" Co-administration of aspirin did not influence the elimination of MTX, but further research is needed"><entity charOffset="22-29" id="DDI-PubMed.28705331.s22.e0" text="aspirin" /><entity charOffset="67-70" id="DDI-PubMed.28705331.s22.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28705331.s22.e0" e2="DDI-PubMed.28705331.s22.e0" /><pair ddi="false" e1="DDI-PubMed.28705331.s22.e0" e2="DDI-PubMed.28705331.s22.e1" /></sentence><sentence text="" /></document>